Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus
Vaccine, Volume 27, No. 33, Year 2009
Notification
URL copied to clipboard!
Description
We describe the development and preliminary characterization of a recombinant canarypox virus vectored (ALVAC®) vaccine for protective immunization of equids against African horse sickness virus (AHSV) infection. Horses (n = 8) immunized with either of two concentrations of recombinant canarypox virus vector (ALVAC-AHSV) co-expressing synthetic genes encoding the outer capsid proteins (VP2 and VP5) of AHSV serotype 4 (AHSV-4) developed variable titres (<10-80) of virus-specific neutralizing antibodies and were completely resistant to challenge infection with a virulent strain of AHSV-4. In contrast, a horse immunized with a commercial recombinant canarypox virus vectored vaccine expressing the haemagglutinin genes of two equine influenza H3N8 viruses was seronegative to AHSV and following infection with virulent AHSV-4 developed pyrexia, thrombocytopenia and marked oedema of the supraorbital fossae typical of the "dikkop" or cardiac form of African horse sickness. AHSV was detected by virus isolation and quantitative reverse transcriptase polymerase chain reaction in the blood of the control horse from 8 days onwards after challenge infection whereas AHSV was not detected at any time in the blood of the ALVAC-AHSV vaccinated horses. The control horse seroconverted to AHSV by 2 weeks after challenge infection as determined by both virus neutralization and ELISA assays, whereas six of eight of the ALVAC-AHSV vaccinated horses did not seroconvert by either assay following challenge infection with virulent AHSV-4. These data confirm that the ALVAC-AHSV vaccine will be useful for the protective immunization of equids against African horse sickness, and avoids many of the problems inherent to live-attenuated AHSV vaccines. © 2009 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Guthrie, Alan John
Unknown Affiliation
Quan, Melvyn
Unknown Affiliation
Lourens, Carina W.
Unknown Affiliation
Audonnet, Jean Christophe
Unknown Affiliation
Minke, Julius Maarten H.M.
Unknown Affiliation
Yao, Jiansheng
Unknown Affiliation
He, Ling
Unknown Affiliation
Nordgren, Robert M.
Unknown Affiliation
Gardner, Ian Andrew
Unknown Affiliation
MacLachlan, Nigel James
Unknown Affiliation
Statistics
Citations: 69
Authors: 10
Affiliations: 6
Identifiers
Doi:
10.1016/j.vaccine.2009.05.044
ISSN:
0264410X
Research Areas
Maternal And Child Health
Noncommunicable Diseases
Study Approach
Quantitative